Pliant Therapeutics Provides Corporate Update and Reports First Quarter 2024 Financial Results
06 mai 2024 16h05 HE
|
Pliant Therapeutics, Inc.
BEACON-IPF pivotal, adaptive Phase 2b/3 trial design implementation significantly accelerates bexotegrast development in IPF Data from completed 12 week Phase 2a imaging trial measuring bexotegrast’s...
Pliant Therapeutics to Participate in Upcoming Investor Events
01 mai 2024 08h00 HE
|
Pliant Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., May 01, 2024 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical-stage biotechnology company and leader in the discovery and development of novel...
Pliant Therapeutics to Participate in Upcoming Investor Events
02 avr. 2024 08h00 HE
|
Pliant Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., April 02, 2024 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical-stage biotechnology company and leader in the discovery and development of novel...
Pliant Therapeutics Announces Upcoming Presentations at the 2024 American Thoracic Society International Conference
27 mars 2024 10h23 HE
|
Pliant Therapeutics, Inc.
Bexotegrast clinical poster selected for featured oral presentation at ATS 2024 Mini Symposium SOUTH SAN FRANCISCO, Calif., March 27, 2024 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq:...
Pliant Therapeutics Announces Accelerated Bexotegrast Development Plan for the Treatment of Idiopathic Pulmonary Fibrosis
12 mars 2024 07h30 HE
|
Pliant Therapeutics, Inc.
Acceptance by European Union and other global health authorities of the pivotal, adaptivePhase 2b/3 trial will significantly shorten bexotegrast’s time to Phase 3 data Upsized Oxford Finance debt...
Pliant Therapeutics Provides Corporate Update and Reports Fourth Quarter 2023 Financial Results
27 févr. 2024 16h03 HE
|
Pliant Therapeutics, Inc.
Positive interim 12-week safety and efficacy data reported from Phase 2a INTEGRIS-PSC trial in patients with PSC Enrollment continues in BEACON-IPF, a Phase 2b trial in patients with IPF SOUTH...
Pliant Therapeutics to Participate in Upcoming Investor Conferences
26 févr. 2024 08h00 HE
|
Pliant Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., Feb. 26, 2024 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical-stage biotechnology company and leader in the discovery and development of novel...
Pliant Therapeutics to Participate in Upcoming Investor Events
07 févr. 2024 08h00 HE
|
Pliant Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., Feb. 07, 2024 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical-stage biotechnology company and leader in the discovery and development of novel...
Pliant Therapeutics Announces Positive Safety and Exploratory Efficacy Data from the INTEGRIS-PSC Phase 2a Trial of Bexotegrast 320 mg in Patients with Primary Sclerosing Cholangitis and Suspected Liver Fibrosis
04 févr. 2024 15h29 HE
|
Pliant Therapeutics, Inc.
Bexotegrast (PLN-74809) at 320 mg was well tolerated over 12 weeks of treatment with no drug-related severe or serious adverse events; No safety concerns identified across all dose cohorts ...
Pliant Therapeutics to Participate in the 42nd Annual J.P. Morgan Healthcare Conference
03 janv. 2024 08h00 HE
|
Pliant Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., Jan. 03, 2024 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX) today announced that Bernard Coulie, M.D., Ph.D., President and Chief Executive Officer, is...